Overview

Novel therapies for soft tissue and bone sarcomas

Positions

Professor of Medicine in the School of Medicine

2024 School of Medicine

Member of the Duke Cancer Institute in the School of Medicine

2000 School of Medicine

Education

M.D., Thomas Jefferson University 2000

2000 Thomas Jefferson University

Resident in Medicine, Duke University, Medicine 2000 - 2003

2003 Duke University

Fellow in Hematology-Oncology, Duke University, Medicine 2003 - 2004

2004 Duke University

Fellow in Hematology-Oncology, Duke University, Medicine 2005 - 2007

2007 Duke University

Clinical Trials

EA7211 STRASS 2 High Risk Retroperitoneal Sarcoma

Servier "CHONQUER" (IDH1-mutated locally advanced or metastatic chondrosarcoma)

ECOG EA7222 Doxo + pembro vs Doxorubicin for undifferentiated pleomorphic and related sarcomas

Invincible-3 Trial (Recurrent, Metastatic Soft Tissue Sarcoma)

KURA KO-MEN-015 Advanced Gastrointestinal Stromal Tumors

Load More

Publications, Grants & Awards

• Grants (41)
• Academics Articles (110)
• Conference Pages (49)
• Book Sections (3)

Showing 1 - 5 of 41

A Phase 1a/1b Study of the Safety, Pharmacokinetics, and Antitumor Activity of the Oral Menin Inhibitor Ziftomenib in Combination with Imatinib in Patients with Advanced Gastrointestinal Stromal Tumors (GIST) After Imatinib Failure

2025-2030Kura Oncology, Inc.

A Phase II, Multi-centre, Randomised, Double-blind, Group Comparator Trial to Assess the Safety and Efficacy of Emactuzumab vs. Placebo in Patients with Tenosynovial Giant Cell Tumour,

2025-2030SynOx Therapeutics Ltd

A Multicenter, Randomized, Phase 3 Study to Assess the Efficacy and Safety of INtratumorally Administered INT230-6 (SHAO, VINblastine, CIsplatin) Compared With US Standard of Care in Adult Participants With Locally Recurrent, InoperaBLE,orMetastatic

2024-2029Intensity Therapeutics, Inc.

A Phase 3, multicenter, double-blind, randomized, placebo-controlled study of ivosidenib in participants ?18 years of age with locally advanced or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1

2024-2029Servier Bio-Innovation, LLC

Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies

2023-2029Adaptimmune LLC

DCI Centers, Cancer Types & Labs

Duke Sarcoma Center

Offices & Contact

Dept of Medicine
Durham, NC
27710

Duke Box 3198
Durham, NC
27710